BREAST CANCER PANEL 4

ER & PR receptor assays are routinely performed on Breast carcinoma to assess responsiveness to endocrine therapy and prognosis. Her-2 expression predicts responsiveness to Herceptin therapy. Ki-67 in addition is a useful prognositc marker. Together ER, PR, Her-2 and Ki 67 help to predict prognosis and serve as surrogate IHC markers for molecular subtypes of Breast Cancer.

  • Test Type:
  • Pre-test Information:
    Provide a copy of the Histopathology report, Clinical history & indicate site of biopsy.
  • Report Delivery:
    Sample Daily by 6 pm; Report Block : 5 days Tissue biopsy : 5 days Tissue large complex : 7 days
  • Components:
    0